Skip to main content
SRZN
NASDAQ Life Sciences

Surrozen Q3: $129.7M Non-Cash Loss, Boehringer Arbitration Disclosed, Cash Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$32
Mkt Cap
$376.114M
52W Low
$11.51
52W High
$37.83
52W Position info
178% above low
Off High info
15% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $11.51 on light trading volume (0.2× avg).

Summary

Surrozen's Q3 loss was $129.7 million, but $113.0 million of that was non-cash warrant and tranche remeasurement. The filing also reveals Boehringer Ingelheim has filed for arbitration over their collaboration, while October financings push the cash runway into 2029.


Key Events · Earnings and Guidance · SRZN

  • Q3 Loss Is Mostly Non-Cash

    Net loss of $129.7 million for Q3 2026 included $113.0 million of non-cash losses on changes in fair value of tranche and warrant liabilities, driven primarily by the increase in the stock price — not a cash outflow.

  • Boehringer Files ICC Arbitration

    In October 2026 Boehringer Ingelheim filed an ICC arbitration request alleging material breach of the CLA and seeking a 50% cut to royalty and milestone obligations plus repayment of $5.0 million of the June 2026 milestone; Surrozen denied the claims in full in November 2026.

  • $5.0M Milestone Constrained

    Surrozen recognized only $5.0 million of the $10.0 million June 2026 development milestone (a 50% reduction) and booked the remaining $5.0 million received in September 2026 as accrued liabilities rather than revenue.

  • Cash Runway Extended Into 2029

    Cash and cash equivalents were $100.4 million at September 30, 2026; October 2026 brought $95.1 million gross from the 2025 PIPE second tranche, $29.8 million net from 2026 ATM sales and $1.1 million from warrant exercises, funding operations into 2029.


Analysis · SRZN · Life Sciences

The $129.7 million Q3 net loss is almost entirely accounting noise: $113.0 million of it is non-cash remeasurement of the tranche and warrant liabilities, driven by the rising share price rather than any cash outflow. The real news buried in the 10-Q is that Boehringer Ingelheim has taken Surrozen to ICC arbitration, seeking to halve its royalty and milestone obligations and claw back $5.0 million of the June 2026 milestone. Surrozen has already stopped counting that $5.0 million as revenue and parked it in accrued liabilities, so a chunk of the partnership economics is now contested. Against that, the balance sheet is solid: $100.4 million of cash at quarter-end plus roughly $126 million raised in October (the $95.1 million PIPE tranche, $29.8 million of ATM sales and $1.1 million of warrant exercises) funds operations into 2029, covering the DUET Phase 1b/2a readouts.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $32.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $376.1M. The 52-week trading range was $11.51 to $37.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.00 info
Change: $0 (0%) info
Market Cap: $376.114M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.00 info
Change: $0 (0%) info
Market Cap: $376.114M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $32.00 info
Change: +$6.86 (+27%) info
Market Cap: $376.114M info
SRZN
Oct 02, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $32.00 info
Change: +$1.87 (+6%) info
Market Cap: $376.114M info
SRZN
Oct 02, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $32.00 info
Change: +$1.87 (+6%) info
Market Cap: $376.114M info